| __timestamp | Supernus Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5758000 | 570979 |
| Thursday, January 1, 2015 | 8423000 | 2185000 |
| Friday, January 1, 2016 | 11986000 | 4554000 |
| Sunday, January 1, 2017 | 15215000 | 3605000 |
| Monday, January 1, 2018 | 15356000 | 5527000 |
| Tuesday, January 1, 2019 | 16660000 | 5234000 |
| Wednesday, January 1, 2020 | 52459000 | 6126000 |
| Friday, January 1, 2021 | 75061000 | 6784000 |
| Saturday, January 1, 2022 | 87221000 | 7592000 |
| Sunday, January 1, 2023 | 83779000 | 11450000 |
Cracking the code
In the ever-evolving landscape of biopharmaceuticals, understanding cost structures is pivotal. Supernus Pharmaceuticals, Inc. and Travere Therapeutics, Inc. offer a fascinating glimpse into this dynamic. Over the past decade, Supernus Pharmaceuticals has seen a staggering 1,355% increase in its cost of revenue, peaking in 2022. This growth reflects their aggressive expansion and investment in innovative treatments. Meanwhile, Travere Therapeutics, Inc. has experienced a more modest 1,905% rise, indicating a steady yet strategic approach to scaling operations.
From 2014 to 2023, Supernus Pharmaceuticals consistently outpaced Travere Therapeutics in cost of revenue, highlighting their larger operational scale. However, Travere's recent surge in 2023, with a 51% increase from the previous year, suggests a potential shift in strategy. These insights underscore the importance of cost management in driving sustainable growth in the biopharmaceutical sector.
Cost of Revenue Comparison: Sanofi vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Comparison: Zoetis Inc. vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
BeiGene, Ltd. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Catalent, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Lantheus Holdings, Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cytokinetics, Incorporated vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: CRISPR Therapeutics AG vs Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Veracyte, Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Who Generates Higher Gross Profit? Supernus Pharmaceuticals, Inc. or Travere Therapeutics, Inc.